The trial, which will enroll 45 patients at 14 medical centers across the US and Canada, will evaluate Xcytrin in combination with whole brain radiation therapy and stereotactic radiosurgery.
“For select patients with a limited number of brain metastases, stereotactic radiosurgery is becoming a widely-used treatment. This trial is intended to demonstrate that Xcytrin can improve treatment outcome in patients with brain metastases who are treated with stereotactic radiosurgery,” said Dr Minesh Mehta, professor and chairman of human oncology at the University of Wisconsin Medical School.
Dr Mehta also said that the study should show that Xcytrin can be used alongside magnetic resonance imaging to produce better images of tumors and help radiosurgeons to define the treatment field.